Inventor · disambiguated record
Charles A. Glass
Also filed as: GLASS CHARLES · GLASS CHARLES A
19 granted patents·10 pending applications·151 citations·filing 2000–2022
94Inventor score
Files withBIOMARIN PHARM INC12CRAWFORD BRETT E7TEGA THERAPEUTICS INC5ORTHO MCNEIL PHARM INC3ZACHARON PHARMACEUTICALS INC2
Top patents by PatentIndex Score
29 records- 0195US8232073B2Quantification of non-reducing end glycan residual compoundsCRAWFORD BRETT E·Filed 2009·Granted Jul 31, 2012·35 cites·15 claims
- 0294US9340822B2Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2014·Granted May 17, 2016·12 cites·23 claims
- 0394US8809009B2Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2012·Granted Aug 19, 2014·14 cites·16 claims
- 0494US8771974B2Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorderCRAWFORD BRETT E·Filed 2012·Granted Jul 8, 2014·16 cites·21 claims
- 0592US9915649B2Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVABIOMARIN PHARM INC·Filed 2016·Granted Mar 13, 2018·4 cites·34 claims
- 0692US9222120B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2014·Granted Dec 29, 2015·13 cites·21 claims
- 0792US8183003B2Polymer end group detectionCRAWFORD BRETT E·Filed 2009·Granted May 22, 2012·22 cites·11 claims
- 0890US9677116B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2015·Granted Jun 13, 2017·4 cites·30 claims
- 0988US10260084B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2017·Granted Apr 16, 2019·2 cites·12 claims
- 1086US8592140B2Detection of oligosaccharidesCRAWFORD BRETT E·Filed 2009·Granted Nov 26, 2013·12 cites·15 claims
- 1183US9029530B2Detection of oligosaccharidesCRAWFORD BRETT E·Filed 2009·Granted May 12, 2015·4 cites·5 claims
- 1276US6455278B1DNA encoding human vanilloid receptor VR3ORTHO MCNEIL PHARM INC·Filed 2000·Granted Sep 24, 2002·7 cites·9 claims
- 1375US10793894B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2019·Granted Oct 6, 2020·0 cites·20 claims
- 1474US9796999B2Detection of oligosaccharidesBIOMARIN PHARM INC·Filed 2015·Granted Oct 24, 2017·1 cites·28 claims
- 1572US7186803B2Human vanilloid receptor VR3 proteinORTHO MCNEIL PHARM INC·Filed 2004·Granted Mar 6, 2007·4 cites·2 claims
- 1672US2021025874A1Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2020·Application pending·0 cites
- 1770US11549000B2Cellular glycosaminoglycan compositions and methods of making and usingTEGA THERAPEUTICS INC·Filed 2016·Granted Jan 10, 2023·1 cites·10 claims
- 1870US2021017570A1Detection of oligosaccharidesBIOMARIN PHARM INC·Filed 2020·Application pending·0 cites
- 1969US10677786B2Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2018·Granted Jun 9, 2020·0 cites·21 claims
- 2068US2024026404A1Cellular glycosaminoglycan compositions and methods of making and usingTEGA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2167US10683530B2Detection of oligosaccharidesBIOMARIN PHARM INC·Filed 2017·Granted Jun 16, 2020·0 cites·8 claims
- 2252US7094877B2Human vanilloid receptor VR3 proteinORTHO MCNEIL PHARM INC·Filed 2002·Granted Aug 22, 2006·0 cites·2 claims
- 2352US2010048638A1Heparan sulfate inhibitorsZACHARON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2451US2024301092A1Heparin from modified mst cells and methods of making and usingTEGA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2539US2022305049A1Heparin and heparan sulfate from modified mst cells and methods of making and usingTEGA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2637US2012295890A1Glycosaminoglycan inhibitorsCRAWFORD BRETT E·Filed 2010·Application pending·0 cites
- 2734US2010248365A1Ganglioside biosynthesis modulatorsZACHARON PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 2833US2012100609A1N-linked glycan biosynthesis modulatorsCRAWFORD BRETT E·Filed 2010·Application pending·0 cites
- 2929US2020038430A1In vitro heparin and heparan sulfate compositions and methods of making and usingTEGA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charles A. Glass files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →